A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3

BACKGROUND: The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths combining 9 repurposed non-oncological drugs with metronomic temozolomide—version 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Halatsch, Marc-Eric, Kast, Richard E, Karpel-Massler, Georg, Mayer, Benjamin, Zolk, Oliver, Schmitz, Bernd, Scheuerle, Angelika, Maier, Ludwig, Bullinger, Lars, Mayer-Steinacker, Regine, Schmidt, Carl, Zeiler, Katharina, Elshaer, Ziad, Panther, Patricia, Schmelzle, Birgit, Hallmen, Anke, Dwucet, Annika, Siegelin, Markus D, Westhoff, Mike-Andrew, Beckers, Kristine, Bouche, Gauthier, Heiland, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349180/
https://www.ncbi.nlm.nih.gov/pubmed/34377985
http://dx.doi.org/10.1093/noajnl/vdab075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349180/
https://www.ncbi.nlm.nih.gov/pubmed/34377985
http://dx.doi.org/10.1093/noajnl/vdab075

Ejemplares similares